The House Committee on Oversight and Reform has launched a wide-ranging investigation into prescription drug pricing in the United States.
Yesterday, the House Committee on Oversight and Reform launched a wide-ranging investigation into prescription drug pricing in the United States.
The committee’s chair, Representative Elijah Cummings, D-Maryland, sent letters to 12 drug makers seeking information and documents related to pricing practices. According to the committee’s statement, the letters seek further information about price increases, investments in research and development, and corporate strategies to defend market share. The committee will next hold a series of hearings on drug pricing.
“The Committee on Oversight and Reform is investigating the actions of drug companies in raising prescription drug prices in the United States, as well as the effects of these actions on federal and state budgets and on American families,” Cummings wrote in a statement announcing the investigation. “For years, drug companies have been aggressively increasing prices on existing drugs and setting higher launch prices for new drugs while recording windfall profits. The goals of this investigation are to determine why drug companies are increasing prices so dramatically, how drug companies are using the proceeds, and what steps can be taken to reduce prescription drug prices.”
Among the products that are subject to the investigation are AbbVie’s brand-name adalimumab, Humira; Amgen’s etanercept, Enbrel; and Sanofi’s insulin glargine, Lantus. All 3 of these products are the targets of as-yet unrealized biosimilar and follow-on competition:
Additional products that are subject to the committee’s investigation are cancer drugs imatinib (Novartis’ Gleevec) and lenalidomide (Celgene’s Revlimid), pain drug pregabalin (Pfizer’s Lyrica), and glatiramer acetate (Teva’s Copaxone), among others.
Biosimilars in America: Overcoming Barriers and Maximizing Impact
July 21st 2024Join us as we explore the complexities of the US biosimilars market, discussing legislative influences, payer and provider adoption factors, and strategies to overcome industry challenges with expert insights from Kyle Noonan, PharmD, MS, value & access strategy manager at Cencora.
Hesitancy in MENA Nations to Adopt WHO Biosimilar Guidelines Hinders Market Development
July 17th 2024The World Health Organization’s (WHO) new guidelines for biosimilar approvals aim to save time and money for manufacturers in the Middle East and North Africa (MENA), but hesitancy among nations to adopt the guidelines is stifling market development of biosimilars.
Biosimilars Policy Roundup for April 2024—Podcast Edition
May 5th 2024On this episode of Not So Different, The Center for Biosimilars® glances back at all the major biosimilar policy updates from April, including 2 FDA approvals, 1 European approval, and several insights into possible policy changes from the Festival of Biologics USA conference.